Hepatitis C virus infection entered a new era this year, following FDA
approvals of multiple treatment regimens, and new, groundbreaking
clinical data produced by the top researchers in the field. Using web
analytics, social media and expert opinion, Healio.com/Hepatology
has compiled a list of some of the most important, relevant research
and news on hepatitis C virus infection presented during the past year.
FDA approves Harvoni for HCV treatment
Using the breakthrough therapy designation,
the FDA approved the first combination pill for treatment of chronic
hepatitis C virus genotype 1 that does not require interferon or
ribavirin for administration.
Treatment-naive participants showed a 94%
sustained virologic response rate after 8 weeks of treatment and a 96%
SVR rate after 12 weeks. Treatment-naive patients with and without
cirrhosis showed a 99% SVR rate after 12 weeks. Among
treatment-experienced participants with and without cirrhosis, ribavirin
did not improve response rates in any of the trials.
Labels: Top HCV stories of 2014